Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $10.00 Average Price Target from Brokerages

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has earned an average recommendation of “Moderate Buy” from the five analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $10.00.

VTYX has been the topic of several recent research reports. Oppenheimer restated an “outperform” rating and set a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. HC Wainwright reissued a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th.

Ventyx Biosciences Price Performance

Shares of VTYX stock opened at $2.35 on Tuesday. The company has a market cap of $166.17 million, a PE ratio of -1.00 and a beta of 0.48. The stock’s 50 day simple moving average is $2.30 and its two-hundred day simple moving average is $2.34. Ventyx Biosciences has a 1 year low of $1.67 and a 1 year high of $11.48.

Insider Buying and Selling at Ventyx Biosciences

In related news, CEO Raju Mohan acquired 261,752 shares of the stock in a transaction on Monday, November 25th. The stock was bought at an average cost of $2.01 per share, with a total value of $526,121.52. Following the transaction, the chief executive officer now directly owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider John Nuss sold 13,161 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the transaction, the insider now directly owns 485,701 shares in the company, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.18% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ventyx Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Ventyx Biosciences in the second quarter valued at about $32,000. Bank of New York Mellon Corp raised its holdings in shares of Ventyx Biosciences by 58.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 230,593 shares of the company’s stock valued at $533,000 after purchasing an additional 84,984 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Ventyx Biosciences by 38.0% in the 2nd quarter. Rhumbline Advisers now owns 90,331 shares of the company’s stock worth $209,000 after purchasing an additional 24,885 shares during the period. Acadian Asset Management LLC bought a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $608,000. Finally, American Century Companies Inc. purchased a new position in Ventyx Biosciences during the second quarter valued at approximately $60,000. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.